SH-BC-893

SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity.

SH-BC-893 starves cancer cells to death by down-regulating cell surface nutrient transporters and blocking lysosomal trafficking events^[1].
SH-BC-893 (5 μM; 3 h) protects from ceramide-induced mitochondrial network fragmentation by disrupting intracellular trafficking^[2].
SH-BC-893 (8.935 nM; 3 h) protects from ceramide-induced mitochondrial dysfunction^[2].

SH-BC-893 (oral; 120 mg/kg; single) robustly and acutely blocks ceramide-induced mitochondrial dysfunction, correcting diet-induced obesity and its metabolic sequelae^[1].

References:
[1]. Kubiniok, Peter et al. Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs. Molecular & cellular proteomics : MCP vol. 18,3 (2019): 408-422.
[2]. Jayashankar, Vaishali et al. Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity. EMBO molecular medicine vol. 13,8 (2021): e13086.